Abstract:Background & aims Hyperglycemia is associated with lipid disorders in patients with diabetes. Ceramides are metabolites involved in sphingolipid metabolism that accumulate during lipid disorders and exert deleterious effects on glucose and lipid metabolism. However, the effects of ceramide on glucagon-mediated hepatic gluconeogenesis remain largely unknown. This study was designed to investigate the impact of ceramides on gluconeogenesis in the context of the hepatic glucagon response, with the aim of finding new pharmacological interventions for hyperglycemia in diabetes. Methods Liquid chromatography-mass spectrometry was used to quantify ceramide content in the serum of patients with diabetes. Primary hepatocytes were isolated from male C57BL/6J mice to study the effects of ceramide on hepatic glucose production. Immunofluorescence staining was performed to view cAMP-responsive element-binding protein (CREB)- regulated transcription co-activator 2 (CRTC2) nuclear translocation in hepatocytes. Serine palmitoyl-transferase, long chain base subunit 2 ( Sptlc2 ) knockdown mice were generated using an adeno-associated virus containing shRNA, and hepatic glucose production was assessed glucagon tolerance and pyruvate tolerance tests in mice fed a normal chow diet and high-fat diet. Results Increased ceramide levels were observed in the serum of patients newly diagnosed with type 2 diabetes. De novo ceramide synthesis was activated in mice with metabolic disorders. Ceramide enhanced hepatic glucose production in primary hepatocytes. In contrast, genetic silencing of Sptlc2 prevented this process. Mechanistically, ceramides de-phosphorylate CRTC2 (Ser 171) and facilitate its translocation into the nucleus for CREB activation, thereby augmenting the hepatic glucagon response. Hepatic Sptlc2 silencing blocked ceramide generation in the liver and thus restrained the hepatic glucagon response in mice fed a normal chow diet and high-fat diet. Conclusions These data indicate that ceramide serves as an intracellular messenger that augments hepatic glucose production by regulating CRTC2/CREB activity in the context of the hepatic glucagon response, suggesting that CRTC2 phosphorylation might be a potential node for pharmacological interventions to restrain the hyperglycemic response during fasting in diabetes.

Glucagon-induced Extracellular Camp Regulates Hepatic Lipid Metabolism.

Regulation Of Glucose Homeostasis And Lipid Metabolism By Ppp1r3g-Mediated Hepatic Glycogenesis

Glucagon Attenuates Lipid Accumulation in Cow Hepatocytes Through AMPK Signaling Pathway Activation.

Metabolic Crosstalk: Molecular Links Between Glycogen and Lipid Metabolism in Obesity

Hepatic Glucagon Action - Beyond Glucose Mobilization

Ceramide enhanced the hepatic glucagon response through regulation of CREB activity

Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis

Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice

AMPK-dependent Regulation of GLP1 Expression in L-like Cells.

AMPK-PPARγ-Cidec Axis Drives the Fasting-Induced Lipid Droplet Aggregation in the Liver of Obese Mice

Histone Phosphorylation Integrates the Hepatic Glucagon-Pka-creb Gluconeogenesis Program in Response to Fasting.

AMPK Activation Prevents Excess Nutrient-Induced Hepatic Lipid Accumulation by Inhibiting Mtorc1 Signaling and Endoplasmic Reticulum Stress Response.

Mechanisms by Which Glucagon Acutely Stimulates Hepatic Mitochondrial Oxidation and Gluconeogenesis

CREB mediates glucagon action to upregulate hepatic MPC1: inhibitory effect of ginsenoside Rb1 on hepatic gluconeogenesis.

The regulation of adipose tissue on gluconeogenesis

Prevention of Hepatic Steatosis and Hepatic Insulin Resistance by Knockdown of Camp Response Element-Binding Protein.

Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes

Glucose availability but not changes in pancreatic hormones sensitizes hepatic AMPK activity during nutritional transition in rodents

Inactivation of NF-κB2 (p52) Restrains Hepatic Glucagon Response Via Preserving PDE4B Induction

Circulating Concentrations of Cathelicidin Anti-Microbial Peptide (CAMP) Are Increased during Oral Glucose Tolerance Test

Glucagon-like peptide-1 receptor mediates the improvement in glycolipid metabolism disorder via AKT and AMPK signalling pathways in L02 cells with insulin resistance